Biotech · Private company · La Jolla, CA, US
Longboard Pharmaceuticals, Inc.
SEC CIK 0001832168
Track this companyFree. Adds Longboard Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials63 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- LP352Phase 3 · Developmental and Epileptic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
- LP352Phase 3 · Dravet SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- LP352, bexicaserinPhase 2 · Developmental and Epileptic EncephalopathyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)PHASE3 · ENROLLING_BY_INVITATION · started Feb 12, 2025ClinicalTrials.gov NCT06908226 · fetched Nov 12, 2026
- A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 11, 2024ClinicalTrials.gov NCT06719141 · fetched Nov 12, 2026
- A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)PHASE3 · ACTIVE_NOT_RECRUITING · started Sep 25, 2024ClinicalTrials.gov NCT06660394 · fetched Nov 12, 2026
- Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic EncephalopathyPHASE2 · COMPLETED · started Nov 8, 2022ClinicalTrials.gov NCT05626634 · fetched Nov 12, 2026
- Study to Investigate LP352 in Subjects With Developmental and Epileptic EncephalopathiesPHASE1_PHASE2 · COMPLETED · started Mar 3, 2022ClinicalTrials.gov NCT05364021 · fetched Nov 12, 2026
- Intermediate-Size Expanded Access Protocol (EAP) for LP352AVAILABLEClinicalTrials.gov NCT06149663 · fetched Nov 12, 2026